Exenatide Medicine 07 December 2021 Extended indication Extension of indication to include the treatment of type 2 diabetes in adolescents and children aged 10 years and above Therapeutic value No estimate possible yet Total cost Registration phase Registration application pending Product Active substance Exenatide Domain Metabolism and Endocrinology Reason of inclusion Indication extension IND Main indication Diabetes Extended indication Extension of indication to include the treatment of type 2 diabetes in adolescents and children aged 10 years and above Current proprietary name Already available biosimilars / generics Proprietary name Bydureon Manufacturer AstraZeneca Portfolio holder Mechanism of action Unknown Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Decentralised Type of trajectory Unknown Particularity Unknown ATMP No Submission date August 2021 Expected Registration June 2022 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks